United Homes Group stock plunges after Nikki Haley, directors resign
Director Guy Archibald Innes of Volitionrx LTD (NASDAQ:VNRX) has purchased 96,153 shares of common stock at $0.51 per share, totaling $49,038. The purchase comes as the stock trades near its 52-week low of $0.40, having declined nearly 29% in the past week. According to InvestingPro analysis, the stock is currently trading below its Fair Value, despite the company’s weak financial health indicators.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction occurred on October 14, 2025. Innes also acquired 96,153 warrants to buy common stock at $0.01 per warrant. With a market capitalization of just $47.6 million, such insider transactions can be significant indicators. InvestingPro subscribers can access comprehensive insider trading analysis and 8 additional ProTips about VNRX’s financial position.
Following the transaction, Innes directly owns 1,062,967 shares of Volitionrx LTD. He also indirectly owns 1,400,000 shares through The Innes Family Bare Trust 2023, 356,000 shares through The Dill Faulkes Educational Trust Limited, and 154,503 and 154,504 shares by son and daughter respectively. The director’s continued investment comes despite the company’s challenging cash position and negative EBITDA of -$22.4 million in the last twelve months.
In other recent news, VolitionRx Limited announced the pricing of an underwritten public offering expected to raise approximately $6 million before expenses. This offering includes 11,550,000 shares of common stock and accompanying warrants, each priced at $0.52, with warrant exercise prices set at $0.60 per share. The company plans to use the proceeds for research, product development, clinical studies, commercialization efforts, working capital, and potential strategic acquisitions. Newbridge Securities Corporation is acting as the sole book-running manager for this transaction, with a 30-day option to purchase an additional 15% of the shares and warrants. In analyst ratings, H.C. Wainwright has reiterated its Buy rating on VolitionRx, maintaining a $2.50 price target following a co-marketing agreement with Hologic Diagenode. This agreement allows Hologic Diagenode to co-market Volition’s Nu.Q Discover service for an initial one-year term. Meanwhile, Benchmark has maintained its Hold rating on the company without specifying a price target. These developments come as VolitionRx continues to focus on its strategic growth initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.